Arteriosclerosis Clinical Trial
Official title:
Mindfulness-Based Stress Reduction and Myocardial Ischemia
Verified date | May 2016 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
The principal objective of the study is to evaluate the effectiveness of a widely used
complementary medicine intervention, mindfulness-based stress reduction (MBSR), in which
mindfulness meditation and yoga are the principal components in the treatment of a chronic,
often fatal illness that affects tens of millions of Americans. The investigators propose to
conduct a single center randomized controlled trial in which 150 patients will be assigned
to either a mindfulness meditation condition, a disease education control condition, or a
stress-monitoring usual care control condition. They will test the following specific
hypotheses:
1. In comparison to either of the control conditions, significantly more coronary artery
disease (CAD) patients in the mindfulness meditation condition will demonstrate
reductions in mental stress-induced ischemia.
2. The ratio of low-to-high frequency of spectral power in heart rate variability during
ambulatory monitoring will be significantly decreased following the participation in a
stress reduction program compared with those in a disease education or usual care
condition.
3. Patients in the mindfulness meditation condition will report greater improvement in
quality of life (i.e., reductions in general psychological symptomology, anger,
anxiety, depression, and daily stress, along with increases in optimism and stress
coping efficacy) than patients in either of the control conditions.
4. Day-to-day variability in self-reported mental stress will be inversely related to
day-to-day stress coping efficacy in the entire sample and time spent in mindfulness
practice in the active treatment condition, and these relationships will be maintained
over a 3-month follow-up.
5. Patients with CAD and mental stress ischemia who show an *abnormal peripheral artery
response during baseline studies will show a significant improvement after mindfulness
intervention.
- Abnormal responses will be defined as peripheral arterial tonometry (PAT) tracings
that decrease greater than 20% in amplitude during mental stress.
Status | Completed |
Enrollment | 150 |
Est. completion date | August 2008 |
Est. primary completion date | August 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - At least 18 years old - Confirmed CAD--the clinical diagnosis of coronary disease will be defined by the presence of at least one of the following: 1) abnormal coronary angiogram; 2) abnormal intravascular ultrasound (IVUS); or 3) abnormal flow reserve and documentation of one of the following: 1) elevated troponin laboratory values typical for myocardial infarction; 2) electrocardiogram (ECG) that shows q-wave abnormalities; 3) nuclear scan that demonstrates a fixed wall motion abnormality consistent with an old myocardial infarct; 4) greater than 95% probability of coronary disease according to the criteria of Diamond and Forrester.102; 5) radionuclide study, dobutamine, or exercise echocardiographic study consistent with stress-induced ischemia (development of segmental wall motion abnormalities or reversible perfusion defects on radionuclide imaging and/or wall motion or systolic thickening abnormalities on stress echocardiographic exam) Exclusion Criteria: - Current pregnancy or probability of pregnancy during the duration of the 12-week study - Diagnosis of unstable angina in the prior 2 months - Presence of other severe, complicating medical problems that will significantly shorten the patients' life expectancy such that they will not be expected to live for the 12 weeks of this study - Presence of serious psychopathology evidenced by BDI scores that indicate a clinically critical level of depression (score of 24 or above) with suicidal ideation; previous diagnosis of an organic mental disorder, schizophrenia, or any psychotic disorder; or psychiatric inpatient at any time during the last 5 years (if patients are excluded on the basis of depression scores indicating severe depression or suicidal ideation, referral for psychological services will be offered) - Post-traumatic stress disorder (PTSD) greater than the 30% VA disability assignment (patients with less severe PTSD will be encouraged to participate) - Existing meditation practice - Weight more than 400 pounds |
Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Florida | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Psychological stress-induced ischemia (measured by radionuclide imaging at Week 9) | After data collection is complete. | No | |
Primary | Heart rate variability (measured by AECG at Week 9) | After data collection is complete | No | |
Primary | Peripheral artery response (measured by finger plethysmography at Week 9) | After data collection is complete | No | |
Primary | Psychological functioning (degree of depression measured by Beck Depression Inventory (BDI), anxiety by STAI, hostility by Cook-Medley Index, anger by STAXI, optimism by LOT-R, and quality of life/functional status by SF-36 at Weeks 9 and 20) | Results of BDI will be assessed immediately after the participant completes the form. All other questionnaires will be assessed after data collection is complete. | No | |
Primary | Daily mood diaries (obtained at Weeks 7-8 and Weeks 20-21) | After data collection is complete | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Not yet recruiting |
NCT02866656 -
The Clinical Research of Low Intensity Continuous Ultrasonic on Lower Limb Arteriosclerosis Occlusion(ASO) Syndrome
|
N/A | |
Completed |
NCT02510547 -
Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial
|
Phase 4 | |
Completed |
NCT02264717 -
Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease
|
N/A | |
Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
Active, not recruiting |
NCT00154180 -
Kronos Early Estrogen Prevention Study (KEEPS)
|
Phase 4 | |
Recruiting |
NCT04343209 -
Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)
|
||
Not yet recruiting |
NCT06039748 -
Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
|
||
Recruiting |
NCT04142021 -
Safety and Feasibility Evaluation of Planning and Execution of Surgical Revascularization Solely Based on Coronary CTA and FFRCT in Patients With Complex Coronary Artery Disease (FASTTRACK CABG)
|
||
Recruiting |
NCT06008756 -
MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
|
Phase 3 | |
Completed |
NCT03253692 -
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
|
||
Active, not recruiting |
NCT04624854 -
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
|
Phase 4 | |
Active, not recruiting |
NCT02921230 -
Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery
|
N/A | |
Recruiting |
NCT01774058 -
The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation
|
Phase 2 | |
Terminated |
NCT01462721 -
The eSVS® Mesh Randomized Post-Market Study
|
N/A | |
Completed |
NCT01221610 -
BIOLUX P-I First in Man Study
|
N/A | |
Completed |
NCT01455974 -
The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients
|
N/A | |
Active, not recruiting |
NCT00174902 -
The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00863967 -
Early Detection of Arteriosclerosis
|
N/A | |
Completed |
NCT00050817 -
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
|
Phase 3 |